NOTIFICATION TO STOCK EXCHANGE
COMPANY STATEMENT
“This is to inform you that Biocon Pharma Limited, a wholly owned subsidiary of the Company, has received approval for Tacrolimus capsule in 0.5mg, 1mg and 5mg strengths, from the National Medical Products Administration (NMPA), China. Tacrolimus is an immunosuppressant used in the treatment of organ transplant patients, which reduces the body’s ability to reject a transplanted organ.
The approval further adds to Biocon’s portfolio of complex drug products and will be commercialised in the region expeditiously.”
Download Company Statement
